Department of Radiation Oncology, Wayne State University/Barbara A. Karmanos Cancer Center, Detroit, Michigan.
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Pract Radiat Oncol. 2013 Oct-Dec;3(4):e149-55. doi: 10.1016/j.prro.2013.02.001. Epub 2013 Mar 13.
The purpose of this study was to identify factors associated with cardiac toxicity in patients treated with chemoradiation therapy (CRT) for esophageal carcinoma.
One hundred twenty-seven patients with adenocarcinoma or squamous cell carcinoma of the esophagus treated from July 2002 to June 2011 at 2 academic institutions with preoperative or definitive CRT were retrospectively reviewed. Association of cardiac toxicity with a number of variables was investigated, including heart disease, cardiac bypass and angioplasty, diabetes, insulin use, smoking, chemotherapy regimen, and tumor location. T test assessed risk of cardiac toxicity secondary to age. Dose volume histograms (DVH) were evaluated for percentage of heart volume receiving >20, 30, 40, and 50 Gy (V20-V50). The Fisher exact test analyzed for an association between dose volume parameters and cardiac toxicity.
Patient population included 100 men and 27 women with a mean age of 64 years. Median follow-up was 12.7 months (range, 0.3-99.6 months). Any cardiac toxicity occurred in 28 patients, the majority of which were pericardial effusion (23/28). Odds ratio for toxicity in women was 4.15 (95% confidence interval [CI], 1.63-10.50; P = .0017) and time to cardiac toxicity by sex was significant (P = .0003). Patients above the median cutoff for V20, V30, and V40 had increased odds of developing cardiac toxicity (P = .03, .008, .002). There was 4.0 increased odds of developing cardiac toxicity with V40 >57% (95% CI, 1.5-10.3, P = .002). On multivariable logistic regression analysis, sex was the only variable associated with any cardiac toxicity and pericardial effusion (P = .0016, P = .0038). None of the other investigated variables were associated with increased risk of cardiac toxicity.
Female patients and dose greater than the median for V20-V40 were associated with the development of cardiac toxicity, specifically pericardial effusion. These data suggest exercising increased care when designing radiation fields in women undergoing CRT for esophageal carcinoma, as pericardial effusion may be a long-term complication.
本研究旨在确定接受放化疗(CRT)治疗食管癌患者发生心脏毒性的相关因素。
回顾性分析 2002 年 7 月至 2011 年 6 月在 2 所学术机构接受术前或根治性 CRT 的 127 例腺癌或食管鳞状细胞癌患者。研究了心脏毒性与多种变量的相关性,包括心脏病、心脏搭桥和血管成形术、糖尿病、胰岛素使用、吸烟、化疗方案和肿瘤位置。t 检验评估了年龄与心脏毒性之间的关系。剂量体积直方图(DVH)评估了心脏接受>20、30、40 和 50Gy(V20-V50)的百分比。Fisher 确切检验分析了剂量体积参数与心脏毒性之间的关系。
患者人群包括 100 名男性和 27 名女性,平均年龄为 64 岁。中位随访时间为 12.7 个月(范围为 0.3-99.6 个月)。28 例患者出现任何心脏毒性,其中大多数为心包积液(23/28)。女性发生毒性的比值比为 4.15(95%置信区间[CI],1.63-10.50;P=.0017),性别与心脏毒性的时间有显著差异(P=.0003)。V20、V30 和 V40 中位数以上的患者发生心脏毒性的几率增加(P=.03、.008、.002)。V40>57%(95%CI,1.5-10.3,P=.002)时,发生心脏毒性的几率增加 4.0 倍。多变量逻辑回归分析显示,性别是唯一与任何心脏毒性和心包积液相关的变量(P=.0016,P=.0038)。其他调查变量均与心脏毒性风险增加无关。
女性患者和 V20-V40 中位数以上的剂量与心脏毒性的发生相关,特别是心包积液。这些数据表明,在为女性食管癌患者设计 CRT 放射野时应格外小心,因为心包积液可能是一种长期并发症。